Brain-computer interface (BCI) company Precision Neuroscience has received an investment from SCI Ventures, a VC firm that claims to hold the world’s first specialist fund dedicated to addressing paralysis.
Backed by notable spinal cord injury advocates such as the Reeve Foundation, SCI’s investment into Precision will provide it with “added momentum” at what the company’s CEO, Michael Mager, views as a pivotal time for BCIs.
Related: Coherence Neuro raises $10M seed round for BCI that aids in cancer treatment
Mager continued in a statement: “People living with paralysis deserve solutions that are safe, effective, and practical to deliver at scale. With SCI Ventures as a partner, we’re one step closer to bringing this transformative technology to those who need it.”
Precision’s BCI, known as Layer 7 Cortical Interface, is primarily being developed to restore communication and control for people with paralysis by translating thoughts into actions, such as typing or controlling devices, and to also enable high-resolution monitoring for patients in neurocritical care. A first-in-human trial of the system was conducted in June 2023, with successful results.
